Sex Differences in the Genetic Causes of Dilated Cardiomyopathy
Mangino M. et al, (2025), Journal of the American College of Cardiology, 86, 400 - 403
Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy
Wang Y-J. et al, (2025), Science Translational Medicine, 17
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Saberi S. et al, (2025), JACC. Heart failure, 13
An ALPK3 truncation variant causing autosomal dominant hypertrophic cardiomyopathy is partially rescued by mavacamten.
Leinhos L. et al, (2025), Sci Rep, 15
Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy
Tadros R. et al, (2025), Nature Genetics
Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings.
Zheng SL. et al, (2025), Nature genetics
Multiparametric cardiovascular magnetic resonance evaluation of myocardial perfusion, oxygenation, and energetics in hypertrophic cardiomyopathy following cardiac myosin inhibitor therapy
Finnigan LEM. et al, (2025), European Heart Journal - Cardiovascular Imaging, 26, 378 - 378
Myocardial disarray and fibrosis across hypertrophic cardiomyopathy stages associate with ECG markers of arrhythmic risk.
Ashkir Z. et al, (2025), European heart journal. Cardiovascular Imaging, 26, 218 - 228
Etiology and Phenotypes of Cardiomyopathy in Southern Africa: The IMHOTEP Multicenter Pilot Study.
Kraus SM. et al, (2024), JACC. Advances, 3
Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.
Tahir UA. et al, (2024), Circulation. Heart failure, 17
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.
Coats CJ. et al, (2024), European heart journal, 45, 4464 - 4478
Flow inefficiencies in non-obstructive HCM revealed by kinetic energy and hemodynamic forces on 4D-flow CMR
Pola K. et al, (2024), European Heart Journal - Imaging Methods and Practice, 2
Genetic therapies for cardiomyopathy: survey of attitudes of the patient community for the CureHeart project
Ormondroyd E. et al, (2024), European Journal of Human Genetics
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Coats CJ. et al, (2024), Journal of the American Heart Association
Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study.
Siontis KC. et al, (2024), European heart journal. Digital health, 5, 416 - 426
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Maron MS. et al, (2024), The New England journal of medicine, 390, 1849 - 1861